Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2021
Event: Consummation of Initial Public Offering (IPO).
Listing: Common stock (Symbol: LUCD) registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
- Shares Offered: 5,000,000 shares of common stock.
- Offering Price: $14.00 per share.
- Gross Proceeds: $70,000,000.
- Underwriting Discounts and Commissions: 7.0% of the aggregate purchase price.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 750,000 additional shares at the IPO price less discounts.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
Material Changes
This filing represents a material change in the company's capital structure and public status. The company transitioned from a private entity to a publicly traded company on The Nasdaq Stock Market LLC. The filing does not provide comparative financial data against a prior period.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful completion of the IPO and lists the underwriting syndicate (Cantor and Canaccord Genuity as joint book-running managers; BTIG and Needham & Company as co-lead managers).
Guidance and Risks: The filing text does not provide specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure of the over-allotment option.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.0% underwriting discount and other offering expenses.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 750,000 shares.
- Review the full S-1 registration statement for detailed financial history, risk factors, and use of proceeds not included in this 8-K.
- Check the press release (Exhibit 99.1) for additional details on the IPO execution.